{
    "info": {
        "nct_id": "NCT03223103",
        "official_title": "Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma (GCO 17-0566)",
        "inclusion_criteria": "* Age ≥ 18\n* Confirmation of GBM (WHO grade IV).\n* Maximal debulking surgery and undergo radiotherapy concomitant with Temozolomide (45-70Gy)\n* Stable disease after treatment of radiation with chemotherapy\n* Life expectancy > 16 weeks.\n* Performance status of 0-2 (Eastern Cooperative Oncology Group).\n* First vaccine treatment start date at least 4 weeks out but not more than 8 weeks from the last dose of concomitant Temozolomide or radiotherapy.\n* Must have tumor tissue sufficient sequencing.\n* Have adequate bone marrow function\n* Require Dexamethasone ≤ 4mg daily on a stable dose\n* Acceptable hematologic, hepatic, and renal function and these tests must be performed within 14 days prior to study\n* The participant must be deemed competent to give informed consent.\n* The participant must agree to use two effective forms of contraception beginning at least four (4) weeks prior to study entry.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Progression of disease at time of screening.\n* Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.\n* Infra-tentorial tumor or multifocal disease.\n* History of hypersensitivity reaction to Temozolomide.\n* Receiving any other investigational agents.\n* Prior history of unrelated neoplastic disease, and having received systemic therapy for the secondary malignancy within the twelve (12) month period preceding the screening evaluation.\n* (HIV/AIDS), Chronic hepatitis B or hepatitis C.\n* History of, or is reasonably suspected to meet criteria for the diagnosis of a known congenital or acquired disorder causing systemic immunosuppression.\n* History of, or is reasonably suspected to meet criteria for the diagnosis of a systemic auto-immune/inflammatory disease or other autoimmune disorder with the exception of: Vitiligo\n* Positive pregnancy test [45 CFR 46.203(b)]. (CFR = Code of Federal Regulations)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have tumor tissue sufficient sequencing.",
            "criterions": [
                {
                    "exact_snippets": "Must have tumor tissue sufficient sequencing",
                    "criterion": "tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sufficiency for sequencing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The participant must agree to use two effective forms of contraception beginning at least four (4) weeks prior to study entry.",
            "criterions": [
                {
                    "exact_snippets": "The participant must agree to use two effective forms of contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of forms",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "forms"
                            }
                        },
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": "effective"
                        }
                    ]
                },
                {
                    "exact_snippets": "beginning at least four (4) weeks prior to study entry",
                    "criterion": "contraception use timing",
                    "requirements": [
                        {
                            "requirement_type": "start time before study entry",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The participant must be deemed competent to give informed consent.",
            "criterions": [
                {
                    "exact_snippets": "deemed competent to give informed consent",
                    "criterion": "competence to give informed consent",
                    "requirements": [
                        {
                            "requirement_type": "competence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acceptable hematologic, hepatic, and renal function and these tests must be performed within 14 days prior to study",
            "criterions": [
                {
                    "exact_snippets": "Acceptable hematologic ... function",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "acceptable"
                        }
                    ]
                },
                {
                    "exact_snippets": "Acceptable ... hepatic ... function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "acceptable"
                        }
                    ]
                },
                {
                    "exact_snippets": "Acceptable ... renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "acceptable"
                        }
                    ]
                },
                {
                    "exact_snippets": "these tests must be performed within 14 days prior to study",
                    "criterion": "laboratory tests timing",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to study"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Performance status of 0-2 (Eastern Cooperative Oncology Group).",
            "criterions": [
                {
                    "exact_snippets": "Performance status of 0-2 (Eastern Cooperative Oncology Group)",
                    "criterion": "Eastern Cooperative Oncology Group (ECOG) performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stable disease after treatment of radiation with chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Stable disease after treatment of radiation with chemotherapy",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "stable disease"
                        }
                    ]
                },
                {
                    "exact_snippets": "after treatment of radiation with chemotherapy",
                    "criterion": "prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "radiation",
                                "chemotherapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmation of GBM (WHO grade IV).",
            "criterions": [
                {
                    "exact_snippets": "Confirmation of GBM (WHO grade IV)",
                    "criterion": "glioblastoma multiforme (GBM) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "WHO grade",
                            "expected_value": "IV"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Require Dexamethasone ≤ 4mg daily on a stable dose",
            "criterions": [
                {
                    "exact_snippets": "Require Dexamethasone ≤ 4mg daily",
                    "criterion": "dexamethasone dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "mg"
                            }
                        },
                        {
                            "requirement_type": "frequency",
                            "expected_value": "daily"
                        }
                    ]
                },
                {
                    "exact_snippets": "on a stable dose",
                    "criterion": "dexamethasone dose",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have adequate bone marrow function",
            "criterions": [
                {
                    "exact_snippets": "Have adequate bone marrow function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age ≥ 18",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* First vaccine treatment start date at least 4 weeks out but not more than 8 weeks from the last dose of concomitant Temozolomide or radiotherapy.",
            "criterions": [
                {
                    "exact_snippets": "First vaccine treatment start date at least 4 weeks out ... not more than 8 weeks from the last dose of concomitant Temozolomide or radiotherapy.",
                    "criterion": "interval between last dose of concomitant Temozolomide or radiotherapy and first vaccine treatment start date",
                    "requirements": [
                        {
                            "requirement_type": "interval",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 8,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy > 16 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy > 16 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 16,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Maximal debulking surgery and undergo radiotherapy concomitant with Temozolomide (45-70Gy)",
            "criterions": [
                {
                    "exact_snippets": "Maximal debulking surgery",
                    "criterion": "debulking surgery",
                    "requirements": [
                        {
                            "requirement_type": "extent",
                            "expected_value": "maximal"
                        }
                    ]
                },
                {
                    "exact_snippets": "undergo radiotherapy concomitant with Temozolomide (45-70Gy)",
                    "criterion": "radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "concomitant therapy",
                            "expected_value": "Temozolomide"
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 45,
                                        "unit": "Gy"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 70,
                                        "unit": "Gy"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Infra-tentorial tumor or multifocal disease.",
            "criterions": [
                {
                    "exact_snippets": "Infra-tentorial tumor",
                    "criterion": "tumor location",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "infra-tentorial"
                        }
                    ]
                },
                {
                    "exact_snippets": "multifocal disease",
                    "criterion": "disease focality",
                    "requirements": [
                        {
                            "requirement_type": "focality",
                            "expected_value": "multifocal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* (HIV/AIDS), Chronic hepatitis B or hepatitis C.",
            "criterions": [
                {
                    "exact_snippets": "HIV/AIDS",
                    "criterion": "HIV/AIDS",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic hepatitis B",
                    "criterion": "chronic hepatitis B",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C",
                    "criterion": "hepatitis C",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progression of disease at time of screening.",
            "criterions": [
                {
                    "exact_snippets": "Progression of disease at time of screening.",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at time of screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of, or is reasonably suspected to meet criteria for the diagnosis of a systemic auto-immune/inflammatory disease or other autoimmune disorder with the exception of: Vitiligo",
            "criterions": [
                {
                    "exact_snippets": "History of, or is reasonably suspected to meet criteria for the diagnosis of a systemic auto-immune/inflammatory disease or other autoimmune disorder with the exception of: Vitiligo",
                    "criterion": "systemic auto-immune/inflammatory disease or other autoimmune disorder (excluding vitiligo)",
                    "requirements": [
                        {
                            "requirement_type": "history or suspicion of diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "vitiligo"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of, or is reasonably suspected to meet criteria for the diagnosis of a known congenital or acquired disorder causing systemic immunosuppression.",
            "criterions": [
                {
                    "exact_snippets": "History of ... a known congenital or acquired disorder causing systemic immunosuppression",
                    "criterion": "congenital or acquired disorder causing systemic immunosuppression",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "reasonably suspected to meet criteria for the diagnosis of a known congenital or acquired disorder causing systemic immunosuppression",
                    "criterion": "congenital or acquired disorder causing systemic immunosuppression",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_suspected",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positive pregnancy test [45 CFR 46.203(b)]. (CFR = Code of Federal Regulations)",
            "criterions": [
                {
                    "exact_snippets": "Positive pregnancy test",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receiving any other investigational agents.",
            "criterions": [
                {
                    "exact_snippets": "Receiving any other investigational agents.",
                    "criterion": "receipt of other investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior history of unrelated neoplastic disease, and having received systemic therapy for the secondary malignancy within the twelve (12) month period preceding the screening evaluation.",
            "criterions": [
                {
                    "exact_snippets": "Prior history of unrelated neoplastic disease",
                    "criterion": "unrelated neoplastic disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "having received systemic therapy for the secondary malignancy within the twelve (12) month period preceding the screening evaluation",
                    "criterion": "systemic therapy for secondary malignancy",
                    "requirements": [
                        {
                            "requirement_type": "receipt of therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.",
            "criterions": [
                {
                    "exact_snippets": "Implanted pacemaker",
                    "criterion": "implanted pacemaker",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "programmable shunts",
                    "criterion": "programmable shunt",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "defibrillator",
                    "criterion": "implanted defibrillator",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "deep brain stimulator",
                    "criterion": "deep brain stimulator",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other implanted electronic devices in the brain",
                    "criterion": "other implanted electronic devices in the brain",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "documented clinically significant arrhythmias",
                    "criterion": "clinically significant arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of hypersensitivity reaction to Temozolomide.",
            "criterions": [
                {
                    "exact_snippets": "History of hypersensitivity reaction to Temozolomide.",
                    "criterion": "hypersensitivity reaction to Temozolomide",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}